Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions: nicotine, varenicline, placebo; Drug · Other
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 120 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Resilient, Empowered, Active Living with Diabetes, Information Control; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 30 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pancreatic Cancer
Interventions: FOLFIRINOX, Losartan, Proton Beam Radiation; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chlamydia Trachomatis Infection, Gonorrhea
Interventions: Ct/GC screening; Other
Lead sponsor: Tulane University; Other
Eligibility: 15 Years to 26 Years · Male only
Enrollment: 1,907 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Diabetes Mellitus
Interventions: InPen Smart insulin pen, traditional/standard insulin pen; Device · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: PF-06291874, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 32
States / cities: Anaheim, California • Los Angeles, California • Orange, California + 28 more

Conditions: Cushings Disease
Interventions: Pasireotide with or without cabergoline; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • Portland, Oregon

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biospecimen Collection, Copper Cu 64-DOTA-A2DM, Positron Emission Tomography, Radioconjugate; Procedure · Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diabetes Mellitus
Interventions: Patient Activation, Provider Training, Quality Improvement, Community Outreach; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 6,209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 6
States / cities: Chicago, Illinois

Conditions: Pediatric Growth Hormone Deficiency
Interventions: Experimental: VRS-317; Drug
Lead sponsor: Versartis Inc.; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 23
States / cities: Clovis, California • Los Angeles, California • San Diego, California + 20 more

Conditions: Healthy, Pituitary Disease, Thyroid Disease
Interventions: TRH (Thyrotropin Releasing Hormone); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Overweight, Obesity, Diabetes Mellitus, Type 2, Insulin Resistance
Interventions: Methylation status; Other
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Type 1 Diabetes
Interventions: Omnipod 5 System; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Palo Alto, California • Santa Barbara, California • Denver, Colorado + 7 more

Conditions: Diabetes
Interventions: Application Validation; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Type 2
Interventions: onyx sorghum, whole wheat flour; Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 30 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: New Haven, Connecticut

Conditions: Hypogonadism, Diabetes, Sarcopenia, Osteoporosis, Depression
Interventions: Androgel (Testosterone Gel), Anastrozole (Aromatase Inhibitor), Placebo tablet, Placebo gel, Calcium Cardone 500mg with vitamin D 400 IU; Drug · Dietary Supplement
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 65 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Endometrial Cancer, Ovarian Cancer
Interventions: quality-of-life assessment; Procedure
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 43
States / cities: Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 36 more

Conditions: Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Pancreatic Polypeptide Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Regional Gastrointestinal Carcinoid Tumor, Somatostatinoma
Interventions: romidepsin, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pancreatic Cancer
Interventions: Stereotactic Body Radiotherapy, Gemcitabine, 4D pancreatic protocol CT scan, FDG PET scan; Radiation · Drug · Other
Lead sponsor: Albert Koong; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Growth Hormone Deficiency, Panhypopituitarism, Short Stature
Interventions: growth hormone; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 8 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Obesity
Interventions: exenatide, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 14
States / cities: Peoria, Arizona • Tucson, Arizona • Santa Ana, California + 11 more

Conditions: Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Interventions: ChemoID Assay, Standard Chemotherapy; Diagnostic Test · Drug
Lead sponsor: Cordgenics, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Los Angeles, California • Miami, Florida • New Orleans, Louisiana + 5 more

Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Interventions: RMC-9805, RMC-6236; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 17
States / cities: Sacramento, California • New Haven, Connecticut • Sarasota, Florida + 12 more

Search by objective public record fields.

Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking

Resilient, Empowered, Active Living: REAL Diabetes Study

Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer

Check it: A New Approach to Controlling Chlamydia Transmission in Young People

Improving Glycemic Control With Telemedicine and Smart Insulin Pens

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer

Improving Diabetes Care and Outcomes on the South Side of Chicago

Versartis Trial in Children to Assess Long-Acting Growth Hormone

Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities

Mitochondrial Methylation in Type 2 Diabetes

Omnipod 5 System Compared to Pump Therapy

Validation of the Diabetes Deep Neural Network Score for Diabetes Mellitus Screening

Investigating the Effect of Onyx Sorghum on Blood Glucose in Individuals With Type 2 Diabetes

Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.

Quality of Life in Survivors of Gynecologic Cancer

This Study is to Evaluate Whether Receiving Education and Glucose Monitoring With the CGM Device Will Improve Patient-reported Outcomes by Improving Patient's Satisfaction and Quality of Life (QOL) With Glucose Monitoring Device

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer

Growth Hormone and Endothelial Function in Children

A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors